Pneumonia Update: Take-Homes from 4 New Studies
Here: highlights of 2 studies on vaccines against pneumonia and 2 studies on resistance to antibiotics commonly used to treat pneumonia.
Here is a very brief overview of 4 very new studies on pneumonia that you could easily have missed. Note: please scroll down for links to article abstracts. ©CPT-Praiseng/Shutterstock.com
A meta-analysis published in PloS One found no evidence that PPV23 prevents pneumococcal CAP in a general community-dwelling elderly population.[1]
There is a need to consider vancomycin heteroresistance in pneumonia caused by MRSA, according to Claeys et al.[2]
Elderly patients with staphylococcal pneumonia are resistant to common antibiotics.[3]
Widespread use of pneumococcal conjugate vaccines for annual flu vaccination has been temporally associated with decreased rates of hospitalization and inpatient mortality, especially in those age 65 and older.[4]
Two new studies have just been published on vaccines against pneumonia along with two studies on resistance to antibioics commonly used to treat pneumonia.
References:
1. Schiffner-Rohe J, et al. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - a systematic review and meta-analysis.PLoS One. 2016 Jan 13;11(1):e0146338. doi: 10.1371/journal.pone.0146338.
2. Claeys KC, et al. Does pneumonia caused by methicillin-resistant Staphyloccus aureus cause vancomycin heteroresistance matter? Antimicrob Agents Chemother. 2016 Jan 4.
3. Yayan J. Rasche K. Growing antibiotic resistance in fatal cases of staphylococcal pneumonia in the elderly. Adv Exp Med Biol. 2016 Jan 9.
4. Change DH, et al. Trends in US hospitalizations and inpatient deaths from pneumonia and influenza, 1996-2011. Vaccine. 2016. Jan 20;34:486-494.
